Low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis jirovecii pneumonia in HIV-uninfected patients: a systematic review and meta-analysis

BackgroundTrimethoprim-sulfamethoxazole (TMP-SMX) is the recommended first-line prophylactic agent against Pneumocystis jirovecii pneumonia (PJP). However, the standard regimen is often discontinued due to its drug-associated adverse events (AEs), especially in immunocompromised patients without HIV...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Hui-Bin Huang, Jia-Heng Shi, Yan-Ge Hu, Yi-Bing Zhu, Da-Xing Yu
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Pharmacology
Assuntos:
Pneumocystis jirovecii pneumonia
trimethoprim-sulfamethoxazole
discontinuation rate
prophylaxis
meta-analysis
Acceso en liña:https://www.frontiersin.org/articles/10.3389/fphar.2025.1545436/full
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares